slides · global inventory
Consultants Gambit
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 39,432
Current window 33,091-33,120
Pages 1,315
Rows per page 30
Arc
33,091-33,120 of 39,432
15
Includes clinical trial data (Study 301) and registry survival analysis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
16
HLR = high-level results; gMG = generalised myasthenia gravis; MG-ADL = myasthenia gravis activities of daily living; QMG = quantitative myasthenia gravis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
17
Includes three distinct data visualizations: a bar chart for median MG-ADL, a box plot for change from baseline, and a line chart for mean MG-ADL over time.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
18
Includes 'Number at risk' table below the x-axis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
20
The slide uses a combination of a timeline/map graphic and a bar chart to demonstrate market penetration and adoption speed.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
21
Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
22
Includes clinical trial design diagram for Part A and Part B.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
23
Includes a biological pathway diagram and a comparison of circulating concentrations.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
24
The slide uses a horizontal timeline-like structure to compare three drug candidates (ALXN2040, ALXN2050, ALXN2080).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
25
Includes FDA Breakthrough Designation callout and trial design diagrams.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
26
The slide uses a human-centric approach to introduce a strategic section.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
27
The slide uses a pyramid to segment the market by patient need and product modality.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
28
Uses a pictograph to represent patient population segments.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
29
The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
31
The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
32
The slide uses a high-emotion photo of a father and son to humanize the medical topic.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
33
The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
34
Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
35
The slide uses a Venn-style diagram to illustrate market expansion.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
36
The slide uses a process diagram to illustrate the pathophysiology of two distinct types of amyloidosis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
37
The slide uses a comparative structure to map assets to specific disease indications and their clinical progress.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a matrix-like layout to categorize drugs by disease area and development stage (marketed, late-stage, early-stage).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
40
The slide uses a circular overlay on a stock photo of a business meeting.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
41
The slide uses a timeline-based map visualization to illustrate market penetration goals.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a map to anchor the geographic focus and a table to list specific drug approvals by disease category.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
43
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
44
The slide uses a bridge metaphor to represent the collaboration between the two entities.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit